Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 18 October, 2025
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 500087 | NSE: CIPLA

Cipla Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 18, 2025, 4:48 pm

Market Cap 1,27,433 Cr.
Current Price 1,578
High / Low 1,612/1,310
Stock P/E23.6
Book Value 386
Dividend Yield0.82 %
ROCE22.7 %
ROE17.8 %
Face Value 2.00
PEG Ratio1.44

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Cipla Ltd

Competitors of Cipla Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 148 Cr. 117 247/84.333.6 46.70.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.96 Cr. 2.07 4.33/1.90 0.570.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 4,702 Cr. 432 440/192105 22.80.16 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 36.4 Cr. 49.0 94.9/37.2 8.730.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 30.0 Cr. 20.4 29.1/17.031.2 6.830.00 %13.5 %11.0 % 10.0
Industry Average19,828.94 Cr1,185.6850.47194.070.34%16.24%14.95%6.10

All Competitor Stocks of Cipla Ltd

Quarterly Result

MetricJun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Sales 5,3755,8295,8105,7396,3296,6786,6046,1636,6947,0517,0736,7306,957
Expenses 4,2324,5264,4034,5664,8354,9444,8564,8474,9785,1655,0845,1925,179
Operating Profit 1,1431,3021,4081,1741,4941,7341,7481,3161,7161,8861,9891,5381,778
OPM % 21%22%24%20%24%26%26%21%26%27%28%23%26%
Other Income 103123114-48136176-10249160191222289259
Interest 18263234162630181815151414
Depreciation 254299272346239290233288247272280309253
Profit before tax 9751,1001,2187451,3751,5941,4741,2591,6111,7891,9161,5041,770
Tax % 28%28%34%30%28%28%28%26%27%27%17%19%27%
Net Profit 7067978085229981,1551,0689321,1751,3051,5751,2141,292
EPS in Rs 8.519.789.926.5112.3314.0113.0811.6314.5816.1319.4515.1316.06

Last Updated: August 1, 2025, 10:40 pm

Below is a detailed analysis of the quarterly data for Cipla Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

  • For Sales, as of Jun 2025, the value is 6,957.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,730.00 Cr. (Mar 2025) to 6,957.00 Cr., marking an increase of 227.00 Cr..
  • For Expenses, as of Jun 2025, the value is 5,179.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5,192.00 Cr. (Mar 2025) to 5,179.00 Cr., marking a decrease of 13.00 Cr..
  • For Operating Profit, as of Jun 2025, the value is 1,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,538.00 Cr. (Mar 2025) to 1,778.00 Cr., marking an increase of 240.00 Cr..
  • For OPM %, as of Jun 2025, the value is 26.00%. The value appears strong and on an upward trend. It has increased from 23.00% (Mar 2025) to 26.00%, marking an increase of 3.00%.
  • For Other Income, as of Jun 2025, the value is 259.00 Cr.. The value appears to be declining and may need further review. It has decreased from 289.00 Cr. (Mar 2025) to 259.00 Cr., marking a decrease of 30.00 Cr..
  • For Interest, as of Jun 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 14.00 Cr..
  • For Depreciation, as of Jun 2025, the value is 253.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 309.00 Cr. (Mar 2025) to 253.00 Cr., marking a decrease of 56.00 Cr..
  • For Profit before tax, as of Jun 2025, the value is 1,770.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,504.00 Cr. (Mar 2025) to 1,770.00 Cr., marking an increase of 266.00 Cr..
  • For Tax %, as of Jun 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 19.00% (Mar 2025) to 27.00%, marking an increase of 8.00%.
  • For Net Profit, as of Jun 2025, the value is 1,292.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,214.00 Cr. (Mar 2025) to 1,292.00 Cr., marking an increase of 78.00 Cr..
  • For EPS in Rs, as of Jun 2025, the value is 16.06. The value appears strong and on an upward trend. It has increased from 15.13 (Mar 2025) to 16.06, marking an increase of 0.93.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 5:30 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 10,17311,34513,79014,39415,15616,36217,13219,16021,76322,75325,77427,54827,811
Expenses 8,0269,18311,31011,89812,32913,26513,92614,90717,21117,72619,48320,42020,621
Operating Profit 2,1472,1632,4802,4962,8263,0973,2064,2524,5535,0276,2917,1287,190
OPM % 21%19%18%17%19%19%19%22%21%22%24%26%26%
Other Income 25116420820828047734426699293552862960
Interest 146168207159114168197161106110906258
Depreciation 3735057541,3231,3231,3261,1751,0681,0521,1721,0511,1071,113
Profit before tax 1,8801,6541,7271,2221,6692,0792,1783,2903,4934,0385,7026,8216,979
Tax % 25%24%19%15%15%27%29%27%27%30%27%22%
Net Profit 1,4041,2291,3831,0351,4171,4921,5002,3892,5472,8334,1545,2695,385
EPS in Rs 17.2914.7116.9312.5117.5218.9619.1829.8231.1934.7151.0565.2866.77
Dividend Payout % 12%14%12%16%17%16%21%17%16%24%25%25%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-12.46%12.53%-25.16%36.91%5.29%0.54%59.27%6.61%11.23%46.63%26.84%
Change in YoY Net Profit Growth (%)0.00%24.99%-37.69%62.07%-31.62%-4.76%58.73%-52.65%4.62%35.40%-19.79%

Cipla Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:9%
5 Years:10%
3 Years:8%
TTM:6%
Compounded Profit Growth
10 Years:16%
5 Years:29%
3 Years:26%
TTM:21%
Stock Price CAGR
10 Years:9%
5 Years:17%
3 Years:15%
1 Year:-4%
Return on Equity
10 Years:13%
5 Years:15%
3 Years:16%
Last Year:18%

Last Updated: September 5, 2025, 2:00 am

Balance Sheet

Last Updated: July 25, 2025, 3:24 pm

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital 161161161161161161161161161161161162
Reserves 9,89010,64111,35612,38314,06814,85115,60218,16520,68023,24626,54531,032
Borrowings 1,2481,7035,2024,1134,0984,3162,8162,0141,056803559438
Other Liabilities 2,1023,1664,3314,2134,3464,4334,8434,5144,9605,0895,2675,702
Total Liabilities 13,40015,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,334
Fixed Assets 6,4966,8309,3689,4929,9509,6089,6839,5169,6839,1609,60710,006
CWIP 4425812,0611,6839816768259697661,0931,1531,566
Investments 7096407599731,2592,5541,4712,7102,5513,6625,4497,933
Other Assets 5,7537,6208,8628,72110,48310,92311,44411,66113,85715,38416,32317,828
Total Assets 13,40015,67021,04920,86922,67323,76223,42324,85526,85729,30032,53337,334

Below is a detailed analysis of the balance sheet data for Cipla Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Mar 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 1.00 Cr..
  • For Reserves, as of Mar 2025, the value is 31,032.00 Cr.. The value appears strong and on an upward trend. It has increased from 26,545.00 Cr. (Mar 2024) to 31,032.00 Cr., marking an increase of 4,487.00 Cr..
  • For Borrowings, as of Mar 2025, the value is 438.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 559.00 Cr. (Mar 2024) to 438.00 Cr., marking a decrease of 121.00 Cr..
  • For Other Liabilities, as of Mar 2025, the value is 5,702.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,267.00 Cr. (Mar 2024) to 5,702.00 Cr., marking an increase of 435.00 Cr..
  • For Total Liabilities, as of Mar 2025, the value is 37,334.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32,533.00 Cr. (Mar 2024) to 37,334.00 Cr., marking an increase of 4,801.00 Cr..
  • For Fixed Assets, as of Mar 2025, the value is 10,006.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,607.00 Cr. (Mar 2024) to 10,006.00 Cr., marking an increase of 399.00 Cr..
  • For CWIP, as of Mar 2025, the value is 1,566.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,153.00 Cr. (Mar 2024) to 1,566.00 Cr., marking an increase of 413.00 Cr..
  • For Investments, as of Mar 2025, the value is 7,933.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,449.00 Cr. (Mar 2024) to 7,933.00 Cr., marking an increase of 2,484.00 Cr..
  • For Other Assets, as of Mar 2025, the value is 17,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,323.00 Cr. (Mar 2024) to 17,828.00 Cr., marking an increase of 1,505.00 Cr..
  • For Total Assets, as of Mar 2025, the value is 37,334.00 Cr.. The value appears strong and on an upward trend. It has increased from 32,533.00 Cr. (Mar 2024) to 37,334.00 Cr., marking an increase of 4,801.00 Cr..

Notably, the Reserves (31,032.00 Cr.) exceed the Borrowings (438.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow - No data available for this post.

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow1.001.00-3.00-2.00-2.00-1.001.002.003.00-798.00-553.00-431.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days596462657593836657656873
Inventory Days273329273239271250267232230228217231
Days Payable92126106108142123139103108112102116
Cash Conversion Cycle239267230196204220211195180181182188
Working Capital Days9389-10991181321139495113120128
ROCE %19%15%13%7%9%11%12%17%17%18%23%23%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
Promoters33.61%33.61%33.55%33.46%33.46%33.46%33.46%30.91%30.93%29.19%29.20%29.19%
FIIs27.69%28.39%27.42%25.49%25.74%25.73%25.82%27.82%28.80%26.65%26.28%25.24%
DIIs21.47%20.87%21.83%24.05%23.90%24.05%24.15%24.66%23.95%27.49%27.89%28.98%
Government0.21%0.21%0.21%0.21%0.21%0.21%0.21%0.21%0.21%0.23%0.26%0.27%
Public17.00%16.91%16.99%16.76%16.68%16.53%16.36%16.40%16.11%16.43%16.36%16.31%
No. of Shareholders3,88,8644,04,1824,75,2934,66,5154,26,8634,25,7314,36,1544,63,5694,70,2345,25,1145,43,4205,49,655

Shareholding Pattern Chart

No. of Shareholders

Cipla Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Flexi Cap Fund - Regular Plan 19,200,000 4.82 2965.0619,200,0002025-04-22 17:25:380%
HDFC ELSS Tax Saver Fund 5,400,000 5.17 833.925,400,0002025-04-22 17:25:380%
HDFC Focused 30 Fund - Regular Plan 4,000,000 4.48 617.724,000,0002025-04-22 17:25:380%
SBI Contra Fund 3,836,985 1.57 592.553,836,9852025-04-22 17:25:380%
SBI Long Term Equity Fund 3,403,528 1.91 525.613,403,5282025-04-22 17:25:380%
HDFC Top 100 Fund - Regular Plan 2,266,282 0.94 349.982,266,2822025-04-22 12:29:180%
Kotak Equity Arbitrage Fund - Regular Plan 2,083,250 0.62 321.722,083,2502025-04-22 17:25:380%
HDFC Balanced Advantage Fund - Regular Plan 1,733,243 0.28 267.661,733,2432025-04-22 17:25:380%
Kotak Equity Opportunities Fund - Regular Plan 1,500,000 0.92 231.651,500,0002025-04-22 17:25:380%
DSP Healthcare Fund 1,386,069 7.77 214.051,386,0692025-04-22 17:25:380%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 65.2951.0534.7231.2029.82
Diluted EPS (Rs.) 65.2451.0134.6931.1729.79
Cash EPS (Rs.) 79.2264.4949.6544.7643.02
Book Value[Excl.RevalReserv]/Share (Rs.) 386.25331.98293.79261.74230.46
Book Value[Incl.RevalReserv]/Share (Rs.) 386.25331.98293.79261.74230.46
Revenue From Operations / Share (Rs.) 341.10319.24281.89269.75237.58
PBDIT / Share (Rs.) 98.9387.1768.1759.9156.03
PBIT / Share (Rs.) 85.2374.1553.6546.8742.79
PBT / Share (Rs.) 84.4670.6250.0343.3040.80
Net Profit / Share (Rs.) 65.5251.4735.1331.7229.78
NP After MI And SOA / Share (Rs.) 65.2951.0534.7131.1929.82
PBDIT Margin (%) 29.0027.3024.1822.2123.58
PBIT Margin (%) 24.9823.2219.0317.3718.01
PBT Margin (%) 24.7622.1217.7416.0517.17
Net Profit Margin (%) 19.2016.1212.4611.7612.53
NP After MI And SOA Margin (%) 19.1315.9912.3111.5612.55
Return on Networth / Equity (%) 16.9015.4311.9612.0713.12
Return on Capital Employeed (%) 21.5721.7917.7817.0416.78
Return On Assets (%) 14.1012.599.509.289.56
Long Term Debt / Equity (X) 0.000.000.000.010.06
Total Debt / Equity (X) 0.000.010.020.030.08
Asset Turnover Ratio (%) 0.780.820.570.510.59
Current Ratio (X) 4.253.713.383.002.88
Quick Ratio (X) 3.222.712.371.911.86
Inventory Turnover Ratio (X) 0.991.000.810.700.87
Dividend Payout Ratio (NP) (%) 19.9116.640.000.000.00
Dividend Payout Ratio (CP) (%) 16.4513.260.000.000.00
Earning Retention Ratio (%) 80.0983.360.000.000.00
Cash Earning Retention Ratio (%) 83.5586.740.000.000.00
Interest Coverage Ratio (X) 128.8578.3050.2345.4528.12
Interest Coverage Ratio (Post Tax) (X) 86.3349.4028.5526.7815.94
Enterprise Value (Cr.) 115819.75120138.5271957.4681343.9366141.15
EV / Net Operating Revenue (X) 4.204.663.163.743.45
EV / EBITDA (X) 14.5017.0713.0816.8314.64
MarketCap / Net Operating Revenue (X) 4.234.683.193.783.43
Retention Ratios (%) 80.0883.350.000.000.00
Price / BV (X) 3.734.523.113.943.59
Price / Net Operating Revenue (X) 4.234.683.193.783.43
EarningsYield 0.040.030.030.030.03

After reviewing the key financial ratios for Cipla Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 65.29. This value is within the healthy range. It has increased from 51.05 (Mar 24) to 65.29, marking an increase of 14.24.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 65.24. This value is within the healthy range. It has increased from 51.01 (Mar 24) to 65.24, marking an increase of 14.23.
  • For Cash EPS (Rs.), as of Mar 25, the value is 79.22. This value is within the healthy range. It has increased from 64.49 (Mar 24) to 79.22, marking an increase of 14.73.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 386.25. It has increased from 331.98 (Mar 24) to 386.25, marking an increase of 54.27.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 386.25. It has increased from 331.98 (Mar 24) to 386.25, marking an increase of 54.27.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 341.10. It has increased from 319.24 (Mar 24) to 341.10, marking an increase of 21.86.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 98.93. This value is within the healthy range. It has increased from 87.17 (Mar 24) to 98.93, marking an increase of 11.76.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 85.23. This value is within the healthy range. It has increased from 74.15 (Mar 24) to 85.23, marking an increase of 11.08.
  • For PBT / Share (Rs.), as of Mar 25, the value is 84.46. This value is within the healthy range. It has increased from 70.62 (Mar 24) to 84.46, marking an increase of 13.84.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 65.52. This value is within the healthy range. It has increased from 51.47 (Mar 24) to 65.52, marking an increase of 14.05.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 65.29. This value is within the healthy range. It has increased from 51.05 (Mar 24) to 65.29, marking an increase of 14.24.
  • For PBDIT Margin (%), as of Mar 25, the value is 29.00. This value is within the healthy range. It has increased from 27.30 (Mar 24) to 29.00, marking an increase of 1.70.
  • For PBIT Margin (%), as of Mar 25, the value is 24.98. This value exceeds the healthy maximum of 20. It has increased from 23.22 (Mar 24) to 24.98, marking an increase of 1.76.
  • For PBT Margin (%), as of Mar 25, the value is 24.76. This value is within the healthy range. It has increased from 22.12 (Mar 24) to 24.76, marking an increase of 2.64.
  • For Net Profit Margin (%), as of Mar 25, the value is 19.20. This value exceeds the healthy maximum of 10. It has increased from 16.12 (Mar 24) to 19.20, marking an increase of 3.08.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 19.13. This value is within the healthy range. It has increased from 15.99 (Mar 24) to 19.13, marking an increase of 3.14.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 16.90. This value is within the healthy range. It has increased from 15.43 (Mar 24) to 16.90, marking an increase of 1.47.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 21.57. This value is within the healthy range. It has decreased from 21.79 (Mar 24) to 21.57, marking a decrease of 0.22.
  • For Return On Assets (%), as of Mar 25, the value is 14.10. This value is within the healthy range. It has increased from 12.59 (Mar 24) to 14.10, marking an increase of 1.51.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. It has decreased from 0.82 (Mar 24) to 0.78, marking a decrease of 0.04.
  • For Current Ratio (X), as of Mar 25, the value is 4.25. This value exceeds the healthy maximum of 3. It has increased from 3.71 (Mar 24) to 4.25, marking an increase of 0.54.
  • For Quick Ratio (X), as of Mar 25, the value is 3.22. This value exceeds the healthy maximum of 2. It has increased from 2.71 (Mar 24) to 3.22, marking an increase of 0.51.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.99. This value is below the healthy minimum of 4. It has decreased from 1.00 (Mar 24) to 0.99, marking a decrease of 0.01.
  • For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 19.91. This value is below the healthy minimum of 20. It has increased from 16.64 (Mar 24) to 19.91, marking an increase of 3.27.
  • For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 16.45. This value is below the healthy minimum of 20. It has increased from 13.26 (Mar 24) to 16.45, marking an increase of 3.19.
  • For Earning Retention Ratio (%), as of Mar 25, the value is 80.09. This value exceeds the healthy maximum of 70. It has decreased from 83.36 (Mar 24) to 80.09, marking a decrease of 3.27.
  • For Cash Earning Retention Ratio (%), as of Mar 25, the value is 83.55. This value exceeds the healthy maximum of 70. It has decreased from 86.74 (Mar 24) to 83.55, marking a decrease of 3.19.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 128.85. This value is within the healthy range. It has increased from 78.30 (Mar 24) to 128.85, marking an increase of 50.55.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 86.33. This value is within the healthy range. It has increased from 49.40 (Mar 24) to 86.33, marking an increase of 36.93.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 115,819.75. It has decreased from 120,138.52 (Mar 24) to 115,819.75, marking a decrease of 4,318.77.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.20. This value exceeds the healthy maximum of 3. It has decreased from 4.66 (Mar 24) to 4.20, marking a decrease of 0.46.
  • For EV / EBITDA (X), as of Mar 25, the value is 14.50. This value is within the healthy range. It has decreased from 17.07 (Mar 24) to 14.50, marking a decrease of 2.57.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.23. This value exceeds the healthy maximum of 3. It has decreased from 4.68 (Mar 24) to 4.23, marking a decrease of 0.45.
  • For Retention Ratios (%), as of Mar 25, the value is 80.08. This value exceeds the healthy maximum of 70. It has decreased from 83.35 (Mar 24) to 80.08, marking a decrease of 3.27.
  • For Price / BV (X), as of Mar 25, the value is 3.73. This value exceeds the healthy maximum of 3. It has decreased from 4.52 (Mar 24) to 3.73, marking a decrease of 0.79.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.23. This value exceeds the healthy maximum of 3. It has decreased from 4.68 (Mar 24) to 4.23, marking a decrease of 0.45.
  • For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Cipla Ltd as of October 20, 2025 is: 1,307.84

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of October 20, 2025, Cipla Ltd is Overvalued by 17.12% compared to the current share price 1,578.00

Intrinsic Value of Cipla Ltd as of October 20, 2025 is: 1,522.89

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of October 20, 2025, Cipla Ltd is Overvalued by 3.49% compared to the current share price 1,578.00

Last 5 Year EPS CAGR: 16.44%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 15.33%, which is a positive sign.
  2. The company has higher reserves (17,371.58 cr) compared to borrowings (2,363.83 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (18.23 cr) and profit (2.77 cr) over the years.
  1. The stock has a high average Working Capital Days of 98.67, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 207.75, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cipla Ltd:
    1. Net Profit Margin: 19.2%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 21.57% (Industry Average ROCE: 16.24%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 16.9% (Industry Average ROE: 14.95%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 86.33
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 3.22
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 23.6 (Industry average Stock P/E: 50.47)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 19044.85 Cr. and Equity Capital is Rs. 161.52 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsCipla House, Peninsula Business Park, Mumbai Maharashtra 400013cosecretary@cipla.com
http://www.cipla.com
Management
NamePosition Held
Dr. Y K HamiedChairman
Mr. Umang VohraManaging Director & Global CEO
Mr. Kamil HamiedNon Exe.Non Ind.Director
Mr. Abhijit JoshiNon Exe.Non Ind.Director
Mr. Adil ZainulbhaiNon Exe.Non Ind.Director
Dr. Balram BhargavaIndependent Director
Dr. Mandar VaidyaIndependent Director
Ms. Maya HariIndependent Director
Mr. P R RameshIndependent Director
Mr. Robert StewartIndependent Director
Ms. Sharmila ParanjpeIndependent Director

FAQ

What is the intrinsic value of Cipla Ltd?

Cipla Ltd's intrinsic value (as of 20 October 2025) is 1307.84 which is 17.12% lower the current market price of 1,578.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,27,433 Cr. market cap, FY2025-2026 high/low of 1,612/1,310, reserves of ₹31,032 Cr, and liabilities of 37,334 Cr.

What is the Market Cap of Cipla Ltd?

The Market Cap of Cipla Ltd is 1,27,433 Cr..

What is the current Stock Price of Cipla Ltd as on 20 October 2025?

The current stock price of Cipla Ltd as on 20 October 2025 is 1,578.

What is the High / Low of Cipla Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Cipla Ltd stocks is 1,612/1,310.

What is the Stock P/E of Cipla Ltd?

The Stock P/E of Cipla Ltd is 23.6.

What is the Book Value of Cipla Ltd?

The Book Value of Cipla Ltd is 386.

What is the Dividend Yield of Cipla Ltd?

The Dividend Yield of Cipla Ltd is 0.82 %.

What is the ROCE of Cipla Ltd?

The ROCE of Cipla Ltd is 22.7 %.

What is the ROE of Cipla Ltd?

The ROE of Cipla Ltd is 17.8 %.

What is the Face Value of Cipla Ltd?

The Face Value of Cipla Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Cipla Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore More Stocks